

Warm Autoimmune Hemolytic Anemia (WAIHA) – Pipeline Insight, 2020

<https://marketpublishers.com/r/WD55CF96B960EN.html>

Date: September 2020

Pages: 70

Price: US\$ 1,500.00 (Single User License)

ID: WD55CF96B960EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Warm Autoimmune Hemolytic Anemia (WAIHA) – Pipeline Insight, 2020," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Warm Autoimmune Hemolytic Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Warm Autoimmune Hemolytic Anemia Understanding

Warm Autoimmune Hemolytic Anemia (WAIHA): Overview

Warm antibody hemolytic anemia is an autoimmune disorder characterized by the premature destruction of healthy red blood cells by autoantibodies. Autoimmune diseases occur when the body's natural defenses against foreign organisms (e.g., lymphocytes, antibodies) destroy healthy tissue for unknown reasons. Normally, red blood cells have a life span of approximately 120 days before they are removed by the spleen. The medical term for low levels of circulating red blood cells is anemia. Anemia may cause fatigue, a pale skin color (pallor), yellowing of the skin and whites of the eyes (jaundice) and the passage of blood in the urine (hemoglobinuria), which gives the

urine a dark brown color. Warm antibody hemolytic anemia is classified as an autoimmune hemolytic anemia (AIHA), an uncommon group of disorders in which the immune system mistakenly attacks healthy red blood cells.

Symptoms

The symptoms of warm antibody hemolytic anemia usually develop slowly over a period of several weeks to months, but in some cases can develop suddenly over a few days. Specific symptoms that occur may vary from one person to another and may depend upon the rate of onset, the rate of destruction of healthy red blood cells and the presence of an underlying disorder. Some individuals, especially those with a gradual onset of anemia, may not have any obvious symptoms (asymptomatic). Affected individuals may eventually develop abnormal paleness of the skin (pallor), fatigue, difficulty breathing upon exertion, dizziness and palpitations. Yellowing of the skin and whites of the eyes (jaundice) and enlargement of the spleen (splenomegaly) are also common findings in individuals with warm antibody hemolytic anemia. Splenomegaly may cause an affected individual to have a bloated or full feeling in the abdomen. Occasionally enlargement of the liver (hepatomegaly) may also occur in some people.

Diagnosis

A diagnosis of hemolytic anemia may be suspected based upon a thorough clinical evaluation, a detailed patient history, identification of characteristic symptoms and a variety of tests such as blood tests that measure hemoglobin and hematocrit. When anemia is suspected to be caused by immune system dysfunction (autoimmune hemolytic anemia), specialized tests such as a Coombs test may be performed. This test is used to detect antibodies that act against red blood cells. A sample of blood is taken and then exposed to the Coombs reagent. A positive test is indicated when the red blood cells clump in the presence of the reagent.

Treatment

The treatment of warm antibody hemolytic anemia is symptomatic and supportive. Affected individuals are usually treated with corticosteroid drugs such as prednisone and can usually be well controlled with proper treatment. A high-dose of these drugs may be initially recommended followed by a gradual reduction (tapering) of the dose over the next few weeks or months. For individuals who do not respond to corticosteroid therapy or develop intolerable side effects, immunosuppressive drugs may be administered or surgical removal of the spleen (splenectomy) may be performed.

Rituximab is a monoclonal antibody, an artificially-created antibody that targets certain white blood cells that create the antibodies which prematurely destroy red blood cells.

Warm Autoimmune Hemolytic Anemia Emerging Drugs Chapters

This segment of the Warm Autoimmune Hemolytic Anemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Warm Autoimmune Hemolytic Anemia Emerging Drugs

Fostamatinib: Rigel Pharmaceuticals

Rigel Pharmaceuticals is conducting a phase 2, multi-center, open label, simon two-stage study to evaluate the safety and efficacy of fostamatinib disodium in the treatment of Warm Antibody Autoimmune Hemolytic Anemia. The purpose of this study is to evaluate whether fostamatinib is safe and effective in the treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA).

BIV009: Bioverativ, a Sanofi company

Sanofi is conducting a prospective, double-blind, randomized, placebo-controlled First-In-Human study with four sub-parts: Part A, a single ascending dose study (SAD) in normal human volunteers (NHVs), Part B, a multiple ascending dose study (MAD) in NHVs, Part C, a multiple dose (MD) study in patients with a complement-mediated disorder, and Part E, a multiple dose (MD) study in patients with cold agglutinin disease previously treated with BIVV009 within the scope of a BIVV009 clinical trial or named patient program use. Note: For parts A-C as well as at the start of part E, study drug was named TNT009. The study drug name is changed to BIVV009 with final version Final 15.0 of the clinical study protocol.

Further product details are provided in the report

Warm Autoimmune Hemolytic Anemia: Therapeutic Assessment

This segment of the report provides insights about the different Warm Autoimmune Hemolytic Anemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Warm Autoimmune Hemolytic Anemia

There are approx. 5+ key companies which are developing the therapies for Warm Autoimmune Hemolytic Anemia. The companies which have their Warm Autoimmune Hemolytic Anemia drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Rigel Pharmaceuticals, Immunovant Sciences GmbH, Apellis Pharmaceuticals, Inc. etc.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Warm Autoimmune Hemolytic Anemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Oral

Intramuscular

Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Polyethylene glycols

Cyclic peptides

Monoclonal antibodies

Immunotherapies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Warm Autoimmune Hemolytic Anemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Warm Autoimmune Hemolytic Anemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Warm Autoimmune Hemolytic Anemia drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Warm Autoimmune Hemolytic Anemia R&D.

The therapies under development are focused on novel approaches to treat/improve Warm Autoimmune Hemolytic Anemia.

ANX005, a clinical-stage investigational monoclonal antibody intended to treat patients with complement-mediated disorders, is currently being evaluated to treat Guillain-Barre Syndrome (GBS), warm autoimmune hemolytic anemia (wAIHA), Huntington's disease (HD) and ALS. Phase 2a trials in patients with HD and ALS and a Phase 2 trial in patients with wAIHA are planned for 2H 2020. A Phase 2/3 trial in patients with GBS is expected to begin in early 2021.

Warm Autoimmune Hemolytic Anemia Report Insights

Warm Autoimmune Hemolytic Anemia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Warm Autoimmune Hemolytic Anemia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Warm Autoimmune Hemolytic Anemia drugs?

How many Warm Autoimmune Hemolytic Anemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Warm Autoimmune Hemolytic Anemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Warm Autoimmune Hemolytic Anemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Warm Autoimmune Hemolytic Anemia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Fostamatinib

Immunovant Sciences GmbH

Apellis Pharmaceuticals, Inc.

Bioverativ

Key Products

Fostamatinib

RVT-1401 680

APL-2

BIV009

Contents

Introduction

Executive Summary

Warm Autoimmune Hemolytic Anemia: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Warm Autoimmune Hemolytic Anemia – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Warm Autoimmune Hemolytic Anemia companies' collaborations, Licensing, Acquisition -Deal Value Trends

Warm Autoimmune Hemolytic Anemia Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Fostamatinib: Rigel Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

APL-2: Apellis Pharmaceuticals, Inc.

Product Description

Research and Development

Product Development Activities

Early Stage Products (Phase II)

BIV009: Bioverativ

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Warm Autoimmune Hemolytic Anemia Key Companies

Warm Autoimmune Hemolytic Anemia Key Products

Warm Autoimmune Hemolytic Anemia- Unmet Needs

Warm Autoimmune Hemolytic Anemia- Market Drivers and Barriers

Warm Autoimmune Hemolytic Anemia- Future Perspectives and Conclusion

Warm Autoimmune Hemolytic Anemia Analyst Views

Warm Autoimmune Hemolytic Anemia Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Warm Autoimmune Hemolytic Anemia

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Warm Autoimmune Hemolytic Anemia

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Warm Autoimmune Hemolytic Anemia (WAIHA) – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/WD55CF96B960EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/WD55CF96B960EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970